In an interview with Targeted Oncology, Jacob Sands, MD, medical oncologist at Dana-Farber Cancer Institute, discusses the ...

Tagrisso with chemo significantly improved survival and progression-free outcomes versus Tagrisso alone in newly diagnosed ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 ...

AstraZeneca has bolstered the standing of Tagrisso as a first-line treatment for locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) with new long-term overall survival (OS) ...

Osimertinib (Tagrisso) has a strong foothold as first-line therapy for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC), but resistance to the third-generation EGFR tyrosine ...

Single-agent osimertinib and the combination demonstrated activity in tumors with MET overexpression, MET amplification, or both. The study population had a median follow-up of 8.2 months.

Osimertinib plus chemotherapy showed a statistically significant improvement in progression-free survival (PFS) vs osimertinib alone in patients with epidermal growth factor receptor–mutated ...

Credit: Getty Images. Osimertinib, a kinase inhibitor, is currently marketed under the brand name Tagrisso. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental ...

At 12 months, 74% (95% CI, 65-80) of patients treated with osimertinib were alive and progression free compared with 22% (95% CI, 13-32) of those who received placebo.

Osimertinib conferred a statistically significant and clinically meaningful improvement in OS compared with placebo among patients with early-stage EGFR-mutated non-small cell lung cancer ...

AstraZeneca’s epidermal growth factor receptor (EGFR) inhibitor, osimertinib (Tagrisso), is on the fast track in 2018 to become a first-line treatment for adult patients with locally-advanced or ...